Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
TherapeuticsMD, Inc.
TXMD · SEC Filings
website
1
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its markete...
Price
1.69
Market Cap
19.81 M
Float
8.55 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about TXMD
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
TherapeuticsMD, Inc.
TXMD · SEC Filings
8.55 M
Float
1.69
Price
19.81 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
News
TYPE
HEADLINE
FILED AT
8-K
TherapeuticsMD Announces Second Quarter 2026 Financial Results
Aug 11, 2026
8-K
TherapeuticsMD Reports First Quarter 2026 Financial Results
May 12, 2026
8-K
TherapeuticsMD Reports Full Year 2025 Financial Results and Ongoing Strategic Review
Mar 30, 2026
8-K
TherapeuticsMD, Inc. Appoints New Independent Auditing Firm
Jan 20, 2026
8-K
TherapeuticsMD, Inc. Holds 2025 Annual Meeting with Key Proposals
Dec 16, 2025
8-K
THERAPEUTICSMD ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS
Nov 12, 2025
Prospectus
TYPE
HEADLINE
FILED AT
424B2
Form 424B2 - Prospectus [Rule 424(b)(2)]
Feb 16, 2021
424B5
Common Stock-
Feb 10, 2021
424B5
ATM | Offering amount: $50,000,000
Nov 27, 2020
424B2
Form 424B2 - Prospectus [Rule 424(b)(2)]
Nov 12, 2020
424B5
PENDING OFFERING | Bank: Cantor
Nov 9, 2020
424B2
Form 424B2 - Prospectus [Rule 424(b)(2)]
Oct 25, 2019
Registrations
TYPE
HEADLINE
FILED AT
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Jul 10, 2023
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Nov 14, 2022
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Oct 17, 2022
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Aug 15, 2022
SC TO-T/A
Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Jul 13, 2022
SC TO-T/A
Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Jul 6, 2022
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 3, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Nov 3, 2025
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Oct 24, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 25, 2024
DEF 14A
Form DEF 14A - Other definitive proxy statements
Oct 25, 2024
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 17, 2023
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G/A
Baselake Partners, LP (Filed by)
Aug 5, 2026
SCHEDULE 13G
Baselake Partners, LP (Filed by)
Apr 6, 2026
4
Thompson Tommy G (Reporting)
Dec 29, 2025
4
Thompson Tommy G (Reporting)
Nov 5, 2025
4
Naughton Gail K (Reporting)
Nov 5, 2025
4
Collins Cooper C. (Reporting)
Nov 5, 2025
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
May 6, 2020
CT ORDER
Form CT ORDER - Confidential treatment order
Apr 10, 2019
CT ORDER
Form CT ORDER - Confidential treatment order
Dec 12, 2018
CT ORDER
Form CT ORDER - Confidential treatment order
Aug 21, 2018
LETTER
Form UPLOAD - SEC-generated letter
Feb 6, 2017
CORRESP
Form CORRESP - Correspondence
Jan 31, 2017
